Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study

Objective: The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) still protracts worldwide. HFB30132A is an anti- SARS-CoV-2 monoclonal antibody purposely engineered for an extended half-life with neutralizing activity against majo...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shanshan, Wu, Xiaojie, Li, Nanyang, Cao, Guoying, Wang, Jingjing, Chen, Yuancheng, Li, Size, He, Jinjie, Wu, Jufang, Yang, Haijing, Lin, Ke, Qiu, Chao, Liu, Angela, Zhou, He, Adrian, Francisco, Schweizer, Liang, Zhang, Wenhong, Gu, Jingwen, Zhang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10269516/
https://www.ncbi.nlm.nih.gov/pubmed/37332355
http://dx.doi.org/10.3389/fphar.2023.1117293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10269516/
https://www.ncbi.nlm.nih.gov/pubmed/37332355
http://dx.doi.org/10.3389/fphar.2023.1117293

Ejemplares similares